Showing results (21-30 of 64) with videos related to

Sort By:
Pageof 7
Neuro-Oncology|October 11, 2017
Divergent evolution of temozolomide resistance in glioblastoma stem cells is reflected in extracellular vesicles and coupled with radiosensitizationDelphine Garnier, Brian Meehan, Thomas Kislinger, et al.
Translational Lung Cancer Research|July 17, 2025
Response of non-small cell lung cancer harboring different epidermal growth factor receptor mutations to ablative radiotherapyAreej Al Rabea, Ian J Gerard, Paul Daniel, et al.
Frontiers in Oncology|June 6, 2019
Radiomics in Glioblastoma: Current Status and Challenges Facing Clinical ImplementationAhmad Chaddad, Michael Jonathan Kucharczyk, Paul Daniel, et al.
Radiation Research|December 21, 2002
Somatic cell mutations at the glycophorin a locus in erythrocytes of radiation workers from the Sellafield nuclear facilityE Janet Tawn, Caroline A Whitehouse, C Paul Daniel, et al.
BMC Health Services Research|October 6, 2019
Can quality improvement improve the quality of care? A systematic review of reported effects and methodological rigor in plan-do-study-act projectsSøren Valgreen Knudsen, Henrik Vitus Bering Laursen, Søren Paaske Johnsen, et al.
Stroke|December 31, 2011
Use of secondary medical prophylaxis and clinical outcome among patients with ischemic stroke: a nationwide follow-up studyKaare Haurvig Palnum, Frank Mehnert, Grethe Andersen, et al.
Cerebrovascular Diseases (Basel, Switzerland)|October 16, 2010
Medical prophylaxis following hospitalization for ischemic stroke: age- and sex-related differences and relation to mortalityKaare Haurvig Palnum, Frank Mehnert, Grethe Andersen, et al.
Journal of Fish Diseases|February 27, 2019
Systemic infection in European perch with thermoadapted virulent Aeromonas salmonicida (Perca fluviatilis)Melanie Rupp, Paola Pilo, Barbara Müller, et al.
Retina (Philadelphia, Pa.)|November 26, 2009
Vitreous nonsteroidal antiinflammatory drug concentrations and prostaglandin E2 levels in vitrectomy patients treated with ketorolac 0.4%, bromfenac 0.09%, and nepafenac 0.1%Jeffrey S Heier, Carl C Awh, Brandon G Busbee, et al.
Glycobiology|April 19, 2020
Ser and Thr acceptor preferences of the GalNAc-Ts vary among isoenzymes to modulate mucin-type O-glycosylationEarnest James Paul Daniel, Matilde Las Rivas, Erandi Lira-Navarrete, et al.
Pageof 7